nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Hyperhidrosis—Vincristine—muscle cancer	0.00285	0.00285	CcSEcCtD
Gadoversetamide—Fatigue—Dactinomycin—muscle cancer	0.00284	0.00284	CcSEcCtD
Gadoversetamide—Back pain—Etoposide—muscle cancer	0.00283	0.00283	CcSEcCtD
Gadoversetamide—Pain—Dactinomycin—muscle cancer	0.00282	0.00282	CcSEcCtD
Gadoversetamide—Muscle spasms—Etoposide—muscle cancer	0.00281	0.00281	CcSEcCtD
Gadoversetamide—Anorexia—Vincristine—muscle cancer	0.00281	0.00281	CcSEcCtD
Gadoversetamide—Eye pain—Doxorubicin—muscle cancer	0.00279	0.00279	CcSEcCtD
Gadoversetamide—Hypotension—Vincristine—muscle cancer	0.00275	0.00275	CcSEcCtD
Gadoversetamide—Feeling abnormal—Dactinomycin—muscle cancer	0.00271	0.00271	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Etoposide—muscle cancer	0.00271	0.00271	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00269	0.00269	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00268	0.00268	CcSEcCtD
Gadoversetamide—Increased appetite—Doxorubicin—muscle cancer	0.00268	0.00268	CcSEcCtD
Gadoversetamide—Insomnia—Vincristine—muscle cancer	0.00266	0.00266	CcSEcCtD
Gadoversetamide—Paraesthesia—Vincristine—muscle cancer	0.00264	0.00264	CcSEcCtD
Gadoversetamide—Malaise—Etoposide—muscle cancer	0.00263	0.00263	CcSEcCtD
Gadoversetamide—Vertigo—Etoposide—muscle cancer	0.00262	0.00262	CcSEcCtD
Gadoversetamide—Abdominal pain—Dactinomycin—muscle cancer	0.0026	0.0026	CcSEcCtD
Gadoversetamide—Body temperature increased—Dactinomycin—muscle cancer	0.0026	0.0026	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Doxorubicin—muscle cancer	0.00258	0.00258	CcSEcCtD
Gadoversetamide—Loss of consciousness—Etoposide—muscle cancer	0.00257	0.00257	CcSEcCtD
Gadoversetamide—Decreased appetite—Vincristine—muscle cancer	0.00256	0.00256	CcSEcCtD
Gadoversetamide—Cough—Etoposide—muscle cancer	0.00255	0.00255	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Vincristine—muscle cancer	0.00254	0.00254	CcSEcCtD
Gadoversetamide—Fatigue—Vincristine—muscle cancer	0.00254	0.00254	CcSEcCtD
Gadoversetamide—Convulsion—Etoposide—muscle cancer	0.00253	0.00253	CcSEcCtD
Gadoversetamide—Hyponatraemia—Doxorubicin—muscle cancer	0.00253	0.00253	CcSEcCtD
Gadoversetamide—Hypertension—Etoposide—muscle cancer	0.00252	0.00252	CcSEcCtD
Gadoversetamide—Pain—Vincristine—muscle cancer	0.00252	0.00252	CcSEcCtD
Gadoversetamide—Constipation—Vincristine—muscle cancer	0.00252	0.00252	CcSEcCtD
Gadoversetamide—Diplopia—Doxorubicin—muscle cancer	0.00252	0.00252	CcSEcCtD
Gadoversetamide—Asthma—Methotrexate—muscle cancer	0.00251	0.00251	CcSEcCtD
Gadoversetamide—Chest pain—Etoposide—muscle cancer	0.00249	0.00249	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00247	0.00247	CcSEcCtD
Gadoversetamide—Discomfort—Etoposide—muscle cancer	0.00246	0.00246	CcSEcCtD
Gadoversetamide—Face oedema—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Gadoversetamide—Hypersensitivity—Dactinomycin—muscle cancer	0.00243	0.00243	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Vincristine—muscle cancer	0.00241	0.00241	CcSEcCtD
Gadoversetamide—Confusional state—Etoposide—muscle cancer	0.0024	0.0024	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Etoposide—muscle cancer	0.00238	0.00238	CcSEcCtD
Gadoversetamide—Asthenia—Dactinomycin—muscle cancer	0.00236	0.00236	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Doxorubicin—muscle cancer	0.00236	0.00236	CcSEcCtD
Gadoversetamide—Dysuria—Methotrexate—muscle cancer	0.00235	0.00235	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Etoposide—muscle cancer	0.00233	0.00233	CcSEcCtD
Gadoversetamide—Tachycardia—Etoposide—muscle cancer	0.00233	0.00233	CcSEcCtD
Gadoversetamide—Body temperature increased—Vincristine—muscle cancer	0.00233	0.00233	CcSEcCtD
Gadoversetamide—Abdominal pain—Vincristine—muscle cancer	0.00233	0.00233	CcSEcCtD
Gadoversetamide—Skin disorder—Etoposide—muscle cancer	0.00232	0.00232	CcSEcCtD
Gadoversetamide—Dry skin—Doxorubicin—muscle cancer	0.00231	0.00231	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Etoposide—muscle cancer	0.0023	0.0023	CcSEcCtD
Gadoversetamide—Anorexia—Etoposide—muscle cancer	0.00227	0.00227	CcSEcCtD
Gadoversetamide—Diarrhoea—Dactinomycin—muscle cancer	0.00225	0.00225	CcSEcCtD
Gadoversetamide—Pneumonia—Methotrexate—muscle cancer	0.00225	0.00225	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Gadoversetamide—Hypotension—Etoposide—muscle cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Muscular weakness—Doxorubicin—muscle cancer	0.00222	0.00222	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00222	0.00222	CcSEcCtD
Gadoversetamide—Conjunctivitis—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Gadoversetamide—Influenza—Doxorubicin—muscle cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Dysphagia—Doxorubicin—muscle cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Asthma—Doxorubicin—muscle cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Hypersensitivity—Vincristine—muscle cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Paraesthesia—Etoposide—muscle cancer	0.00214	0.00214	CcSEcCtD
Gadoversetamide—Haematuria—Methotrexate—muscle cancer	0.00213	0.00213	CcSEcCtD
Gadoversetamide—Dyspnoea—Etoposide—muscle cancer	0.00213	0.00213	CcSEcCtD
Gadoversetamide—Somnolence—Etoposide—muscle cancer	0.00212	0.00212	CcSEcCtD
Gadoversetamide—Epistaxis—Methotrexate—muscle cancer	0.00211	0.00211	CcSEcCtD
Gadoversetamide—Asthenia—Vincristine—muscle cancer	0.00211	0.00211	CcSEcCtD
Gadoversetamide—Vomiting—Dactinomycin—muscle cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Rash—Dactinomycin—muscle cancer	0.00208	0.00208	CcSEcCtD
Gadoversetamide—Decreased appetite—Etoposide—muscle cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Etoposide—muscle cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Fatigue—Etoposide—muscle cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Constipation—Etoposide—muscle cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Pain—Etoposide—muscle cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Dysuria—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Gadoversetamide—Haemoglobin—Methotrexate—muscle cancer	0.00202	0.00202	CcSEcCtD
Gadoversetamide—Diarrhoea—Vincristine—muscle cancer	0.00201	0.00201	CcSEcCtD
Gadoversetamide—Haemorrhage—Methotrexate—muscle cancer	0.00201	0.00201	CcSEcCtD
Gadoversetamide—Pharyngitis—Methotrexate—muscle cancer	0.002	0.002	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Methotrexate—muscle cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Urethral disorder—Methotrexate—muscle cancer	0.00197	0.00197	CcSEcCtD
Gadoversetamide—Feeling abnormal—Etoposide—muscle cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Doxorubicin—muscle cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Nausea—Dactinomycin—muscle cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Pneumonia—Doxorubicin—muscle cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Etoposide—muscle cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Dizziness—Vincristine—muscle cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—muscle cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Urticaria—Etoposide—muscle cancer	0.00189	0.00189	CcSEcCtD
Gadoversetamide—Abdominal pain—Etoposide—muscle cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Body temperature increased—Etoposide—muscle cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Urinary tract infection—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Conjunctivitis—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—muscle cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—muscle cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Vomiting—Vincristine—muscle cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—muscle cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Rash—Vincristine—muscle cancer	0.00186	0.00186	CcSEcCtD
Gadoversetamide—Dermatitis—Vincristine—muscle cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—muscle cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Headache—Vincristine—muscle cancer	0.00184	0.00184	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—muscle cancer	0.00182	0.00182	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—muscle cancer	0.00182	0.00182	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—muscle cancer	0.00182	0.00182	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—muscle cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—muscle cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Gadoversetamide—Hypersensitivity—Etoposide—muscle cancer	0.00176	0.00176	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—muscle cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—muscle cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—muscle cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Nausea—Vincristine—muscle cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—muscle cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—muscle cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—muscle cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—muscle cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—muscle cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Asthenia—Etoposide—muscle cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—muscle cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—muscle cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Pruritus—Etoposide—muscle cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—muscle cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—muscle cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Diarrhoea—Etoposide—muscle cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—muscle cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—muscle cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—muscle cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—muscle cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—muscle cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—muscle cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—muscle cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Dizziness—Etoposide—muscle cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—muscle cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—muscle cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—muscle cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—muscle cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—muscle cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—muscle cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Vomiting—Etoposide—muscle cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Rash—Etoposide—muscle cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Dermatitis—Etoposide—muscle cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Headache—Etoposide—muscle cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—muscle cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—muscle cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—muscle cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—muscle cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—muscle cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—muscle cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—muscle cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Nausea—Etoposide—muscle cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—muscle cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—muscle cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—muscle cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—muscle cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—muscle cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—muscle cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—muscle cancer	0.00137	0.00137	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—muscle cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—muscle cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—muscle cancer	0.00132	0.00132	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—muscle cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—muscle cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—muscle cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—muscle cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—muscle cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—muscle cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—muscle cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—muscle cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—muscle cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—muscle cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—muscle cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—muscle cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—muscle cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—muscle cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—muscle cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—muscle cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—muscle cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—muscle cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—muscle cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—muscle cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—muscle cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—muscle cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—muscle cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—muscle cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—muscle cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—muscle cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—muscle cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—muscle cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—muscle cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—muscle cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—muscle cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—muscle cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—muscle cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—muscle cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—muscle cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—muscle cancer	0.00102	0.00102	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—muscle cancer	0.00102	0.00102	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—muscle cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—muscle cancer	0.000982	0.000982	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—muscle cancer	0.000978	0.000978	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—muscle cancer	0.000978	0.000978	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—muscle cancer	0.000977	0.000977	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—muscle cancer	0.000944	0.000944	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—muscle cancer	0.000911	0.000911	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—muscle cancer	0.000908	0.000908	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—muscle cancer	0.0009	0.0009	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—muscle cancer	0.0009	0.0009	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—muscle cancer	0.000895	0.000895	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—muscle cancer	0.000887	0.000887	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—muscle cancer	0.000875	0.000875	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—muscle cancer	0.000848	0.000848	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—muscle cancer	0.000846	0.000846	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—muscle cancer	0.000818	0.000818	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—muscle cancer	0.000786	0.000786	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—muscle cancer	0.00078	0.00078	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—muscle cancer	0.000779	0.000779	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—muscle cancer	0.000775	0.000775	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—muscle cancer	0.000735	0.000735	CcSEcCtD
